Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Peiwen ¹ , ZHANG Hui ² , LI Mingshuang ³ , CHENG Hanchao ¹ , ZHANG Yuou ¹ ,  SUN Jing ¹ ,  LIN Mengbo ² ,  LIU Yuanli ¹

1. School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100710, P.R.China;
2. Department of Oncology Surgery, Fujian Provincial Hospital, Fuzhou 350001, P.R.China;
3. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100710, P.R.China;

Corresponding?author：

SUN Jing, Email: sunjing@pumc.edu.cn; LIN Mengbo, Email: fzsllmb@123.com; LIU Yuanli, Email: yliu@pumc.edu.cn

Keywords：

Human epidermal growth factor receptor 2 positive; Breast cancer; Quality of life; Influencing factor; Logistic regression; Exact logistic regression

DOI：

10.7507/1672-2531.202011085

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the quality of life (QOL) and its influencing factors of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer returning to social life after treatment.Methods Functional assessment of cancer therapy-breast scale (FACT-B Scale) was adopted to investigate the QOL of the HER2 positive breast cancer survivors, who were admitted and treated during January 2015 and October 2019 in Fujian Provincial Hospital. The demographic, social and economic data, as well as the clinical information of the responded survivors were collected. Logistic regression model was adopted to analyze factors associated with the QOL of the responded survivors.Results A total of 117 responded survivors were included. The median of the FACT-B scale was 106.0 (91.0, 121.3) points out of 148 points (71.6%). With the control of the demographic, social and economic status of the responded survivors, as well as the time from diagnosis and treatment to responding to the follow-up, we found that "having other chronic conditions" was the risk factor for the HER2 positive breast cancer survivors to have higher QOL in the social life after treatment (OR=4.17, 95%CI 1.33 to 15.37, P=0.01).Conclusions The overall QOL of the HER2 positive breast cancer survivors in the social life after treatment was low. "Having other chronic conditions" was the risk factor for the HER2 positive breast cancer survivors to have higher QOL in the social life after treatment.

Citation： ZHANG Peiwen, ZHANG Hui, LI Mingshuang, CHENG Hanchao, ZHANG Yuou, SUN Jing, LIN Mengbo, LIU Yuanli. Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors. Chinese Journal of Evidence-Based Medicine, 2021, 21(5): 532-538. doi: 10.7507/1672-2531.202011085 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	International Agency for Research on Cancer. Estimated number of new cases in 2020, China, females, all ages, 2021-02-04. Available at: https://gco.iarc.fr/today/.
3.	Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 632-641.
4.	朱逸慜, 徐兵河. Her2陽性乳腺癌的精準治療及研究進展. 中國腫瘤外科雜志, 2020, 12(4): 294-300.
5.	Figueroa-Magalh?es MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast, 2014, 23(2): 128-136.
6.	李閣, 谷瑞雪, 劉旭, 等. Her2陽性乳腺癌靶向治療藥物的研究進展. 腫瘤學雜志, 2020, 26(1): 1-6.
7.	中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2019年版). 中國癌癥雜志, 2019, 29(8): 609-679.
8.	Lidgren M, Wilking N, J?nsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res, 2007, 16(6): 1073-1081.
9.	Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat, 2010, 123(2): 507-524.
10.	Lu W, Cui Y, Zheng Y, et al. Impact of newly diagnosed breast cancer on quality of life among Chinese women. Breast Cancer Res Treat, 2007, 102(2): 201-210.
11.	徐巧巧, 呂萍, 顏波兒. 乳腺癌患者術后生存質量及影響因素分析. 預防醫學, 2017, 29(9): 906-908, 913.
12.	閆靜. 乳腺癌患者術后生活質量現狀及影響因素研究. 中國藥物與臨床, 2019, 19(16): 2799-2801.
13.	Ohsumi S, Shimozuma K, Morita S, et al. Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. Jpn J Clin Oncol, 2009, 39(8): 491-496.
14.	Peerawong T, Phenwan T, Supanitwatthana S, et al. Breast conserving therapy and quality of life in thai females: a mixed methods study. Asian Pac J Cancer Prev, 2016, 17(6): 2917-2921.
15.	Nestle-Kr?mling C, Andree C. Treatment quality in breast cancer: numbers, age, and breast reconstruction. Dtsch Arztebl Int, 2015, 112(35-36): 575-576.
16.	Rugo H, Brammer M, Zhang F, et al. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer, 2010, 10(4): 288-293.
17.	Jeffe DB, Pérez M, Cole EF, et al. The effects of surgery type and chemotherapy on early-stage breast cancer patients' quality of life over 2-year follow-up. Ann Surg Oncol, 2016, 23(3): 735-743.
18.	方瓊, 吳怡穎, 沈莉莉, 等. 不同化療階段乳腺癌患者生存質量及影響因素研究. 上海護理, 2019, 19(9): 23-28.
19.	郭雪蓉. 乳腺癌患者生存質量現況及其影響因素研究. 太原: 山西醫科大學, 2011.
20.	Shen FR, Liu M, Zhang X, et al. Health-related quality of life among breast cancer patients and its influencing factor in a Chinese population. Asian Pac J Cancer Prev, 2012, 13(8): 3747-3750.
21.	Khater AI, Noaman MK, Abdel Hafiz MN, et al. Health-related quality of life among egyptian female breast cancer patients at the National Cancer Institute, Cairo University. Asian Pac J Cancer Prev, 2019, 20(10): 3113-3119.
22.	Al-Naggar RA, Nagi NM, Ali MM, et al. Quality of life among breast cancer patients in Yemen. Asian Pac J Cancer Prev, 2011, 12(9): 2335-2341.
23.	FACIT group. Functional Assessment of Cancer Therapy–Breast (FACT-B), 2020-10-03. Available at: https://www.facit.org/measures/FACT-B.
24.	Nguyen J, Popovic M, Chow E, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res, 2015, 4(2): 157-166.
25.	Wan C, Zhang D, Yang Z, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat, 2007, 106(3): 413-418.
26.	中華人民共和國人力資源社會保障部. 關于將36種藥品納入國家基本醫療保險、工傷保險和生育保險藥品目錄乙類范圍的通知(人社部發〔2017〕54號). Available at: http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
27.	福建省醫療保障管理委員會辦公室. 關于轉發人力資源社會保障部將36種藥品納入國家基本醫療保險、工傷保險和生育保險藥品目錄乙類范圍的通知(閩醫保辦〔2017〕70號). Available at: http://www.fuzhou.gov.cn/zgfzzt/sybzx/ylbzjj/zchb/201710/t20171031_1808788.htm.
28.	彭慧, 張一英, 黃芳, 等. 上海市嘉定區女性乳腺癌患者生存質量及影響因素研究. 上海預防醫學, 2016, 28(2): 80-83, 89.
29.	汪敏, 周海濱, 彭績, 等. 武漢市早期乳腺癌患者生命質量及影響因素分析. 公共衛生與預防醫學, 2006, 17(3): 27-30.
30.	Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011, 11: 364.
31.	王懿, 王奕, 吳龍風. 保乳術與改良根治術對乳腺癌患者圍手術期指標生命質量及生存率的影響. 中國藥物與臨床, 2018, 18(9): 1568-1570.
32.	劉啟軍, 曾慶, 周燕榮. 精確logistic回歸及其SAS應用程序. 中華流行病學雜志, 2003, 24(8): 725-728.
33.	王彤, 韓宏. 精確logistic回歸方法及其醫學遺傳學應用. 中國衛生統計, 2003, 20(3): 147-150.
34.	張宏. 精確logistic回歸模型的應用研究. 南京: 東南大學, 1999.
35.	宋秋艷, 余玲, 董瑞鴻. 2型糖尿病對乳腺癌婦女生命質量影響的研究. 中國實用醫藥, 2016, 11(12): 1-3.
36.	孔令泉, 李姝, 伍娟, 等. 關注乳腺癌伴隨疾病全方位管理之. 中華內分泌外科雜志, 2020, 14(2): 89-93.
37.	馬飛, 徐兵河, 邵志敏. 乳腺癌隨訪及伴隨疾病全方位管理指南. 中華腫瘤雜志, 2019, 41(1): 29-41.
38.	黎立喜, 馬飛. 乳腺癌全方位和全周期的健康管理模式. 中國醫學前沿雜志(電子版), 2020, 12(3): 前插1, 1-5.
39.	李波. 關于基層醫院乳腺癌診治現狀的思考. 中華乳腺病雜志(電子版), 2011, 5(5): 512-516.
40.	陳元東, 韋卓, 王源, 等. 乳腺癌診治規范在基層醫院實施情況分析. 中國腫瘤, 2002, 11(12): 707-708.
41.	黃建軍, 吳位龍, 毛大華. 貴州省基層醫院乳腺癌診治現狀調查. 貴陽醫學院學報, 2005, 30(1): 82-83.
42.	穆海英. 醫院-社區-家庭一體化延續護理在乳腺癌術后患者中的應用. 齊魯護理雜志, 2017, 23(14): 40-42.
43.	陳戈, 朱吉, 馬恰怡, 等. 基于綜合醫院-社區協作模式的乳腺癌防治流程構建研究. 中國全科醫學, 2018, 21(19): 2291-2296.
44.	楊智聰, 翟煥聰, 沈艷麗, 等. 家庭醫生式服務模式對社區乳腺癌患者自我感受負擔、負性情緒和生存質量的影響. 中國社區醫師, 2019, 35(34): 184-185, 187.
45.	朱曉靜. 曲妥珠單抗聯合TP化療對HER2陽性乳腺癌患者的影響. 黑龍江醫藥科學, 2020, 43(2): 133-134.
46.	趙敏, 戴成燕, 丁平, 等. 曲妥珠單抗聯合TC化療對HER-2陽性晚期乳腺癌外周血及預后影響. 現代腫瘤醫學, 2020, 28(14): 2431-2435.
47.	董懿, 王鋼樂, 曹技磊. 曲妥珠單抗聯合新輔助化療治療HER2陽性乳腺癌的臨床療效及對患者生存質量的影響. 癌癥進展, 2019, 17(19): 2299-2301.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. International Agency for Research on Cancer. Estimated number of new cases in 2020, China, females, all ages, 2021-02-04. Available at: https://gco.iarc.fr/today/.
3. Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 632-641.
4. 朱逸慜, 徐兵河. Her2陽性乳腺癌的精準治療及研究進展. 中國腫瘤外科雜志, 2020, 12(4): 294-300.
5. Figueroa-Magalh?es MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast, 2014, 23(2): 128-136.
6. 李閣, 谷瑞雪, 劉旭, 等. Her2陽性乳腺癌靶向治療藥物的研究進展. 腫瘤學雜志, 2020, 26(1): 1-6.
7. 中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2019年版). 中國癌癥雜志, 2019, 29(8): 609-679.
8. Lidgren M, Wilking N, J?nsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res, 2007, 16(6): 1073-1081.
9. Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat, 2010, 123(2): 507-524.
10. Lu W, Cui Y, Zheng Y, et al. Impact of newly diagnosed breast cancer on quality of life among Chinese women. Breast Cancer Res Treat, 2007, 102(2): 201-210.
11. 徐巧巧, 呂萍, 顏波兒. 乳腺癌患者術后生存質量及影響因素分析. 預防醫學, 2017, 29(9): 906-908, 913.
12. 閆靜. 乳腺癌患者術后生活質量現狀及影響因素研究. 中國藥物與臨床, 2019, 19(16): 2799-2801.
13. Ohsumi S, Shimozuma K, Morita S, et al. Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. Jpn J Clin Oncol, 2009, 39(8): 491-496.
14. Peerawong T, Phenwan T, Supanitwatthana S, et al. Breast conserving therapy and quality of life in thai females: a mixed methods study. Asian Pac J Cancer Prev, 2016, 17(6): 2917-2921.
15. Nestle-Kr?mling C, Andree C. Treatment quality in breast cancer: numbers, age, and breast reconstruction. Dtsch Arztebl Int, 2015, 112(35-36): 575-576.
16. Rugo H, Brammer M, Zhang F, et al. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer, 2010, 10(4): 288-293.
17. Jeffe DB, Pérez M, Cole EF, et al. The effects of surgery type and chemotherapy on early-stage breast cancer patients' quality of life over 2-year follow-up. Ann Surg Oncol, 2016, 23(3): 735-743.
18. 方瓊, 吳怡穎, 沈莉莉, 等. 不同化療階段乳腺癌患者生存質量及影響因素研究. 上海護理, 2019, 19(9): 23-28.
19. 郭雪蓉. 乳腺癌患者生存質量現況及其影響因素研究. 太原: 山西醫科大學, 2011.
20. Shen FR, Liu M, Zhang X, et al. Health-related quality of life among breast cancer patients and its influencing factor in a Chinese population. Asian Pac J Cancer Prev, 2012, 13(8): 3747-3750.
21. Khater AI, Noaman MK, Abdel Hafiz MN, et al. Health-related quality of life among egyptian female breast cancer patients at the National Cancer Institute, Cairo University. Asian Pac J Cancer Prev, 2019, 20(10): 3113-3119.
22. Al-Naggar RA, Nagi NM, Ali MM, et al. Quality of life among breast cancer patients in Yemen. Asian Pac J Cancer Prev, 2011, 12(9): 2335-2341.
23. FACIT group. Functional Assessment of Cancer Therapy–Breast (FACT-B), 2020-10-03. Available at: https://www.facit.org/measures/FACT-B.
24. Nguyen J, Popovic M, Chow E, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res, 2015, 4(2): 157-166.
25. Wan C, Zhang D, Yang Z, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat, 2007, 106(3): 413-418.
26. 中華人民共和國人力資源社會保障部. 關于將36種藥品納入國家基本醫療保險、工傷保險和生育保險藥品目錄乙類范圍的通知(人社部發〔2017〕54號). Available at: http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
27. 福建省醫療保障管理委員會辦公室. 關于轉發人力資源社會保障部將36種藥品納入國家基本醫療保險、工傷保險和生育保險藥品目錄乙類范圍的通知(閩醫保辦〔2017〕70號). Available at: http://www.fuzhou.gov.cn/zgfzzt/sybzx/ylbzjj/zchb/201710/t20171031_1808788.htm.
28. 彭慧, 張一英, 黃芳, 等. 上海市嘉定區女性乳腺癌患者生存質量及影響因素研究. 上海預防醫學, 2016, 28(2): 80-83, 89.
29. 汪敏, 周海濱, 彭績, 等. 武漢市早期乳腺癌患者生命質量及影響因素分析. 公共衛生與預防醫學, 2006, 17(3): 27-30.
30. Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011, 11: 364.
31. 王懿, 王奕, 吳龍風. 保乳術與改良根治術對乳腺癌患者圍手術期指標生命質量及生存率的影響. 中國藥物與臨床, 2018, 18(9): 1568-1570.
32. 劉啟軍, 曾慶, 周燕榮. 精確logistic回歸及其SAS應用程序. 中華流行病學雜志, 2003, 24(8): 725-728.
33. 王彤, 韓宏. 精確logistic回歸方法及其醫學遺傳學應用. 中國衛生統計, 2003, 20(3): 147-150.
34. 張宏. 精確logistic回歸模型的應用研究. 南京: 東南大學, 1999.
35. 宋秋艷, 余玲, 董瑞鴻. 2型糖尿病對乳腺癌婦女生命質量影響的研究. 中國實用醫藥, 2016, 11(12): 1-3.
36. 孔令泉, 李姝, 伍娟, 等. 關注乳腺癌伴隨疾病全方位管理之. 中華內分泌外科雜志, 2020, 14(2): 89-93.
37. 馬飛, 徐兵河, 邵志敏. 乳腺癌隨訪及伴隨疾病全方位管理指南. 中華腫瘤雜志, 2019, 41(1): 29-41.
38. 黎立喜, 馬飛. 乳腺癌全方位和全周期的健康管理模式. 中國醫學前沿雜志(電子版), 2020, 12(3): 前插1, 1-5.
39. 李波. 關于基層醫院乳腺癌診治現狀的思考. 中華乳腺病雜志(電子版), 2011, 5(5): 512-516.
40. 陳元東, 韋卓, 王源, 等. 乳腺癌診治規范在基層醫院實施情況分析. 中國腫瘤, 2002, 11(12): 707-708.
41. 黃建軍, 吳位龍, 毛大華. 貴州省基層醫院乳腺癌診治現狀調查. 貴陽醫學院學報, 2005, 30(1): 82-83.
42. 穆海英. 醫院-社區-家庭一體化延續護理在乳腺癌術后患者中的應用. 齊魯護理雜志, 2017, 23(14): 40-42.
43. 陳戈, 朱吉, 馬恰怡, 等. 基于綜合醫院-社區協作模式的乳腺癌防治流程構建研究. 中國全科醫學, 2018, 21(19): 2291-2296.
44. 楊智聰, 翟煥聰, 沈艷麗, 等. 家庭醫生式服務模式對社區乳腺癌患者自我感受負擔、負性情緒和生存質量的影響. 中國社區醫師, 2019, 35(34): 184-185, 187.
45. 朱曉靜. 曲妥珠單抗聯合TP化療對HER2陽性乳腺癌患者的影響. 黑龍江醫藥科學, 2020, 43(2): 133-134.
46. 趙敏, 戴成燕, 丁平, 等. 曲妥珠單抗聯合TC化療對HER-2陽性晚期乳腺癌外周血及預后影響. 現代腫瘤醫學, 2020, 28(14): 2431-2435.
47. 董懿, 王鋼樂, 曹技磊. 曲妥珠單抗聯合新輔助化療治療HER2陽性乳腺癌的臨床療效及對患者生存質量的影響. 癌癥進展, 2019, 17(19): 2299-2301.

Chinese Journal of Evidence-Based Medicine

Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content